McDonald's Corp. Outlook Revised to Negative From Stable After Announcement Apr 00

  • ID: 1871281
  • April 2000
  • Standard & Poors
1 of 3

NEW YORK (Standard & Poor's CreditWire) April 20, 2000--Standard & Poor's today revised its outlook on McDonald's Corp. to negative from stable. At the same time, Standard & Poor's affirmed its double-'A' long-term corporate credit, senior unsecured debt, and bank loan ratings and its double-'A'-minus subordinated debt rating on McDonald's. The company's 'A-1'-plus short-term corporate credit and commercial paper ratings were also affirmed. The outlook revision follows management's announcement that the board of directors had approved a $1 billion increase in its three-year share repurchase program to $4.5 billion through 2001. Standard & Poor's believes that this is indicative of a more aggressive financial policy, and could require external financing to be accomplished. In addition, because financial flexibility will not...

Companies mentioned in this report are: McDonald's Corp.
Action: Outlook Revised

Standard and Poors RatingsXpress Credit Research provides in-depth coverage of international corporates, financial institutions, insurance companies, utilities, sovereigns and structured finance programs. RatingsXpress Credit Research lets users determine the credit rating of holdings and identify key factors underlying an issuer's creditworthiness, distinguishes the different risk exposures for new and existing deals, and provides an understanding of how their analysts interpret key regulatory, political and environmental events and their economic impact.

Research type: News
This product is a is a brief one-page announcement of no more than 500 words with a quote from the analyst. It is media and investor focused with no accompanying commentary article.

Note: Product cover images may vary from those shown
2 of 3

McDonald's Corp.

Note: Product cover images may vary from those shown
3 of 3
Note: Product cover images may vary from those shown




Our Clients

  • Fluidigm Corporation
  • Apple, Inc.
  • CEVA Santé Animale
  • Abbott Laboratories Ltd.
  • Merck Group
  • Allergan Inc.
  • Pfizer Inc.